Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Stock market today: Dow slips, S&P 500 and Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose

View original at finance.yahoo.com
Stock market today: Dow slips, S&P 500 and Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose US stocks were mixed on Tuesday as the Federal Reserve's December policy meeting kicked off and federal data showed job openings unexpectedly ticked higher even as layoffs jumped…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Affordability concerns and general uncertainty have led consumers to stay put in their homes

    80% confidence
  • Elevated interest rate and mortgage rate environment since 2020 has stifled housing turnover due to mortgage lobby effect

    80% confidence
  • Consumers remain intentional in their shopping behaviors with at-home-cooking trends continuing to benefit our brands within our Meals & Beverages portfolio that deliver quality, convenience and value

    80% confidence
  • Experiencing soft demand and a choppy housing market this year, though luxury business remains differentiated

    80% confidence
  • OPEC can't really afford a $40 or $30 barrel outcome

    80% confidence
  • Looking for a new Fed chair to immediately move to cut rates

    80% confidence
  • Costs at JPMorgan would rise in 2026 amid competition in credit card space and AI investments driving higher spending

    80% confidence
  • Russia is planning to continue sending uninterrupted fuel supplies to India

    80% confidence
  • While our Snacks business continues to weather category softness, our brands remain highly relevant

    80% confidence
  • Housing turnover has remained at historical lows since 2023, which has significantly reduced demand for projects associated with buying and selling money

    80% confidence
  • Brent crude likely to average $60 through 2026

    80% confidence
  • 55% of US homes are now 40+ years old and will require higher levels of maintenance, repair and renovations in the near future

    80% confidence
  • We believe affordability concerns are pushing the housing market towards equilibrium as home prices are trending towards flat

    80% confidence
  • Exxon is ahead of its 2030 emissions reduction plans

    80% confidence
  • Tesla unsupervised FSD milestone very close

    80% confidence
  • We're observing several dynamics that are pressuring housing and unproven demand

    80% confidence
  • WTI crude expected to trade around $57 in 2026

    80% confidence
  • It would be irresponsible to set out plans for the next six months on rate cuts

    80% confidence
  • Company expects to hit new targets with no increase in capital while generating a 17% return on capital employed

    80% confidence
  • Pent-up demand can be greater than $20 billion and at some point will be a significant tail

    80% confidence
  • Capital for OPEC member countries is not as loose as it was in previous price wars around the 2010s

    80% confidence
  • Several years ago, when we began to transform this company, we did so with one objective: to fully unlock our competitive advantages. Today, our transformation is driving industry-leading results

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com